Core Viewpoint - The company has successfully passed the veterinary drug GMP acceptance and obtained the Veterinary Drug GMP Certificate and Production License, indicating an expansion in its production capabilities and product range in the vaccine and biological products sector [1][2]. Group 1: GMP Certificate and Production License - The company’s Lanzhou branch has received the Veterinary Drug GMP Certificate, which covers the production of various vaccines including inactivated vaccines for foot-and-mouth disease and live vaccines [1]. - The effective period for both the GMP Certificate and the Production License is from January 14, 2026, to January 13, 2031 [1]. Group 2: Production Capabilities and Product Development - The newly approved production lines for cell suspension culture live vaccines and bacterial live vaccines will be utilized for producing vaccines such as the live vaccine for pseudorabies in pigs and the live vaccine for piglet paratyphoid [1]. - The company is in the process of applying for the veterinary product approval numbers for the pseudorabies live vaccine and the piglet paratyphoid live vaccine to expedite their market launch [1]. - The acquisition of the GMP Certificate and Production License signifies that the production lines meet the regulatory requirements, enhancing the company’s core competitiveness and profitability by diversifying its product offerings [2].

Core Viewpoint - The company, Shenlian Biopharmaceutical (Shanghai) Co., Ltd., has signed a project contract with the Lanzhou Veterinary Research Institute to jointly develop multi-valent vaccines for swine and cattle, aiming to enhance disease prevention efficiency and reduce costs [1]. Group 1: Project Collaboration - The collaboration involves the development of multi-valent vaccines targeting three diseases for pigs and three for cattle, with both parties sharing the resulting technology and intellectual property [1]. - Each party will bear its respective costs as per the agreement, indicating a structured approach to resource allocation [1]. Group 2: Market Competitiveness - The anticipated vaccines are expected to achieve "one injection for four protections," which will reduce the number of immunizations required, thereby saving resources and costs while improving production efficiency [1]. - This initiative is projected to enhance the company's competitive edge in the animal health sector by providing comprehensive and efficient disease prevention solutions [1]. Group 3: Future Development Plans - The company plans to strengthen its collaboration with the Lanzhou Veterinary Research Institute, keeping pace with industry trends and accurately addressing changes in prevalent strains and clinical needs [1]. - Future efforts will focus on exploring the application potential of its R&D technology platform, accelerating breakthroughs in other multi-valent vaccines, mRNA vaccines, synthetic peptide vaccines, and virus-like particle (VLP) vaccines [1]. - The goal is to gradually form a clustered product matrix in disease prevention for pigs, ruminants, pets, and aquaculture, continuously enhancing the company's core competitiveness [1].